Home › Breast Cancer › Virginia › Arlington
Breast Cancer clinical trials in Arlington, VA
46 studies for Breast Cancer are looking for participants at sites in and around Arlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · 11 mi away
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RecruitingPhase 3
- Research Site, Fairfax · 11 mi away
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RecruitingPhase 3
- Inova Schar Cancer Institute ( Site 0025), Fairfax · 11 mi away
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RecruitingPhase 2
- Virginia Cancer Specialists, Fairfax · 11 mi away
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Recruiting
- Inova, Fairfax · 11 mi away
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecruitingPhase 3
- Virginia Cancer Specialists, Fairfax · 11 mi away
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RecruitingPhase 2
- Inova Schar Cancer Institute, Fairfax · 11 mi away
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
RecruitingPhase 1
- Next Virginia, Fairfax · 11 mi away
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RecruitingPhase 1/2
- NEXT Oncology, Fairfax · 11 mi away
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RecruitingPhase 1/2
- Inova Schar Cancer Institute, Fairfax · 11 mi away
- Virginia Cancer Specialists, PC, Fairfax · 11 mi away
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi away
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecruitingPhase 3
- Inova Schar Cancer Institute, Fairfax · 11 mi away
- Virginia Cancer Specialists, Fairfax · 11 mi away
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Virginia Cancer Specialists, Fairfax · 11 mi away
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RecruitingPhase 1
- NEXT Oncology, Fairfax · 11 mi away
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RecruitingPhase 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi away
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
RecruitingPhase 1/2
- Next Oncology, Fairfax · 11 mi away
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RecruitingPhase 1/2
- Virginia Cancer Specialists-Fairfax, Fairfax · 11 mi away
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RecruitingPhase 3
- Virginia Cancer Specialists, PC, Fairfax · 11 mi away
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecruitingPhase 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi away
- Kaiser Permanente-Burke Medical Center, Burke · 11 mi away
The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
- Inova Schar Cancer Institute, Fairfax · 11 mi away
- Inova Fair Oaks Hospital, Fairfax · 11 mi away
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
RecruitingPhase 1/2
- NEXT Virginia, Fairfax · 11 mi away
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- NEXT Virginia, Fairfax · 11 mi away
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RecruitingPhase 1
- NEXT Virginia, Fairfax · 11 mi away
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
RecruitingPhase 2
- Virginia Cancer Specialists, Fairfax · 11 mi away
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RecruitingPhase 1
- Inova Schar Cancer Institute, Falls Church · 4 mi away
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RecruitingPhase 3
- Inova Schar Cancer Institute, Fairfax · 11 mi away
- Inova Fair Oaks Hospital, Fairfax · 11 mi away
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RecruitingPhase 3
- Virginia Cancer Specialists, Fairfax · 11 mi away
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- USOR Virginia Cancer Specialists, Fairfax · 11 mi away
E-Mindfulness Approaches for Living After Breast Cancer
RecruitingPhase 3
- Inova Fairfax Hospital, Falls Church · 4 mi away
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi away
- Inova Schar Cancer Institute, Fairfax · 11 mi away
- and 1 more
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
RecruitingPhase 1
- NEXT Virginia, Fairfax · 11 mi away
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
RecruitingPhase 3
- Inova Schar Cancer Institute, Fairfax · 11 mi away
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi away
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
RecruitingPhase 3
- INOVA Schar Cancer, Fairfax · 11 mi away
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecruitingPhase 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi away
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- NEXT, Fairfax · 11 mi away
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
RecruitingPhase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi away
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
RecruitingPhase 1/2
- Inova Schar Cancer Institute ( Site 0051), Fairfax · 11 mi away
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RecruitingPhase 3
- Virginia Cancer Specialists, PC, Reston · 14 mi away
- Virginia Cancer Specialists, Manassas · 22 mi away
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
RecruitingPhase 1
- Virginia Cancer Specialists, Fairfax · 11 mi away
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- NEXT Oncology Virginia, Fairfax · 11 mi away
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- NEXT Virginia, Fairfax · 11 mi away
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecruitingPhase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi away
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RecruitingPhase 1/2
- NEXT, Virginia, Fairfax · 11 mi away
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RecruitingPhase 1
- Inova Schar Cancer Center, Fairfax · 11 mi away
- NEXT Virginia, Fairfax · 11 mi away
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RecruitingPhase 2
- Inova Schar Cancer Institute, Fairfax · 11 mi away
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
RecruitingPhase 1
- Biotheryx Investigative Site, Fairfax · 11 mi away
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY134 studies
- Houston, TX126 studies
- Boston, MA110 studies
- Nashville, TN79 studies
- Los Angeles, CA71 studies
- Edison, NJ69 studies
- St. Louis, MO65 studies
- Durham, NC63 studies
- Queens, NY63 studies
- Chicago, IL58 studies
- Philadelphia, PA56 studies
- Dallas, TX54 studies
Other studies in Arlington
- Non-Small Cell Lung Cancer104 studies
- Metastatic Cancer53 studies
- Colorectal Cancer52 studies
- Cancer (all types)49 studies
- Ovarian Cancer45 studies
- Lung Cancer40 studies
- Endometrial Cancer38 studies
- Pancreatic Cancer35 studies
- Head and Neck Squamous Cell Carcinoma25 studies
- Small Cell Lung Cancer23 studies
- Triple-Negative Breast Cancer20 studies
- Melanoma20 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.